<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lin YS</submitter><funding>National Taiwan University Hospital</funding><funding>Ministry of Education</funding><funding>National Taiwan University</funding><funding>National Health Research Institutes</funding><funding>Academia Sinica</funding><funding>National Science and Technology Council</funding><funding>Kaohsiung Veterans General Hospital</funding><pagination>e20220727</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10174191</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>220(8)</volume><pubmed_abstract>Type I interferons are important antiviral cytokines, but prolonged interferon production is detrimental to the host. The TLR3-driven immune response is crucial for mammalian antiviral immunity, and its intracellular localization determines induction of type I interferons; however, the mechanism terminating TLR3 signaling remains obscure. Here, we show that the E3 ubiquitin ligase ZNRF1 controls TLR3 sorting into multivesicular bodies/lysosomes to terminate signaling and type I interferon production. Mechanistically, c-Src kinase activated by TLR3 engagement phosphorylates ZNRF1 at tyrosine 103, which mediates K63-linked ubiquitination of TLR3 at lysine 813 and promotes TLR3 lysosomal trafficking and degradation. ZNRF1-deficient mice and cells are resistant to infection by encephalomyocard</pubmed_abstract><journal>The Journal of experimental medicine</journal><pubmed_title>The Src-ZNRF1 axis controls TLR3 trafficking and interferon responses to limit lung barrier damage.</pubmed_title><pmcid>PMC10174191</pmcid><funding_grant_id>109-2327-B-002-009</funding_grant_id><funding_grant_id>NTU-CC-111L893903</funding_grant_id><funding_grant_id>110-2634-F-002-044</funding_grant_id><funding_grant_id>AS-CFII-108-104</funding_grant_id><funding_grant_id>ASCFII-108-104</funding_grant_id><funding_grant_id>111C101-7</funding_grant_id><funding_grant_id>108-2320-B-002-020-MY3</funding_grant_id><funding_grant_id>KSVGH110-025</funding_grant_id><funding_grant_id>109-2314-B-002-080</funding_grant_id><funding_grant_id>110L901402B</funding_grant_id><funding_grant_id>NHRI-EX110-11031SI</funding_grant_id><funding_grant_id>109-2320-B-002-018-MY3</funding_grant_id><funding_grant_id>110-2740-B-002-006</funding_grant_id><funding_grant_id>ASIA-106-L04</funding_grant_id><pubmed_authors>Tsai CY</pubmed_authors><pubmed_authors>Ho YH</pubmed_authors><pubmed_authors>Tsai YM</pubmed_authors><pubmed_authors>Lin YS</pubmed_authors><pubmed_authors>Chao TL</pubmed_authors><pubmed_authors>Lai TY</pubmed_authors><pubmed_authors>Lee CY</pubmed_authors><pubmed_authors>Jhuang SJ</pubmed_authors><pubmed_authors>Hsu LC</pubmed_authors><pubmed_authors>Chang SY</pubmed_authors><pubmed_authors>Hsueh YP</pubmed_authors><pubmed_authors>Chang YC</pubmed_authors><pubmed_authors>Chen CY</pubmed_authors><pubmed_authors>Chuang TH</pubmed_authors><pubmed_authors>Liu YL</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Src-ZNRF1 axis controls TLR3 trafficking and interferon responses to limit lung barrier damage.</name><description>Type I interferons are important antiviral cytokines, but prolonged interferon production is detrimental to the host. The TLR3-driven immune response is crucial for mammalian antiviral immunity, and its intracellular localization determines induction of type I interferons; however, the mechanism terminating TLR3 signaling remains obscure. Here, we show that the E3 ubiquitin ligase ZNRF1 controls TLR3 sorting into multivesicular bodies/lysosomes to terminate signaling and type I interferon production. Mechanistically, c-Src kinase activated by TLR3 engagement phosphorylates ZNRF1 at tyrosine 103, which mediates K63-linked ubiquitination of TLR3 at lysine 813 and promotes TLR3 lysosomal trafficking and degradation. ZNRF1-deficient mice and cells are resistant to infection by encephalomyocard</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Aug</publication><modification>2026-07-15T01:42:19.055Z</modification><creation>2025-04-05T21:09:00.33Z</creation></dates><accession>S-EPMC10174191</accession><cross_references><pubmed>37158982</pubmed><doi>10.1084/jem.20220727</doi></cross_references></HashMap>